Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713491 | 0.81 | KDM4E (0.54) | KDM4EALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL1134013 | 0.78 | ALDH1A1 (0.37) | KDM4EALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL12967309 | 0.77 | L3MBTL1 (0.42) | KDM4EALDH1A1L3MBTL1KMT2AMEN1 | |
| SCHEMBL3073989 | 0.77 | LTA4H (0.59) | KDM4EALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL833678 | 0.77 | ALDH1A1 (0.71) | KDM4EALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL9889507 | 0.76 | KDM4E (0.53) | KDM4EALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL1663469 | 0.75 | PARP10 (0.65) | KDM4EALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL5050902 | 0.75 | PARP10 (0.65) | KDM4EALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL31621333 | 0.74 | ALDH1A1 (0.53) | KDM4EALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL3073505 | 0.74 | ALDH1A1 (0.67) | KDM4EALDH1A1SMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232101-A1 | Novel Compounds | CHAPMAN DAVID (SE) | 2012-09-13 | — | — | US | disclosed |
| US-8183251-B2 | 1-[(4S)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]-N-methyl-N-{[4-(pyrimidin-5-yloxy)phenyl]methyl}methanesulfonamide; matrix metalloproteinase inhibitors; obstructive airways disease is asthma or chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2012-05-22 | — | — | US | disclosed |
| EP-2097406-B1 | HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS | ASTRAZENECA AB (SE) | 2011-07-20 | — | — | EP | disclosed |
| EP-2097406-A1 | HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS | Astra Zeneca AB (SE) | 2009-09-09 | — | — | EP | disclosed |
| US-20080221139-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| WO-2008065393-A1 | HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221139-A1 | Novel Compounds | MMP9, MMP2, MMP1 | KDM4E 1320/4885ALDH1A1 282/4885SMN1; SMN2 1975/4885 |
| US-20120232101-A1 | Novel Compounds | MMP9, MMP2, MMP1 | KDM4E 1320/4885ALDH1A1 282/4885SMN1; SMN2 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.